San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Aristea Therapeutics is raising $63,120,986.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, James Mackay played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aristea Therapeutics
Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases. The Aristea team is leveraging its broad industry expertise and proven success in drug development to form synergistic partnerships and build a pipeline of novel drugs. Aristeas lead program, RIST4721, is currently in Phase 2 clinical development.

To learn more about Aristea Therapeutics, visit http://aristeatx.com/

Contact:
James Mackay, President and Chief Executive Officer
858-987-4064
https://www.linkedin.com/in/james-m-mackay/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved